Steering Committee
Amy Abernethy, M.D., Ph.D.
Former Principal Deputy Commissioner
FDA
Chris Arendt, Ph.D.
CSO, Head of Research
Takeda
Jamil Beg
Partner
SV Health Investors
Luciana Borio, M.D.
Venture Partner
Arch Venture Partners
Shelley Chu, M.D., Ph.D.
Partner, Head of Biotech
Lightspeed Ventures
Mark Currie, Ph.D.
Venture Partner
Iaso Ventures
Simone Fishburn, Ph.D.
VP & Editor in Chief
BioCentury Inc.
Todd Foley
Managing Director
MPM BioImpact
Kathleen Giacomini, Ph.D.
Dean, School of Pharmacy
UCSF
David Goldstein, Ph.D.
Co-founder & CEO
Actio Biosciences
Jane Grogan, Ph.D.
EVP, Head of Research
Biogen
Colin Hill
Cofounder and CEO
Aitia
Najat Khan, Ph.D.
Chief R&D Officer and Chief Commercial Officer
Recursion Pharmaceuticals
Sophie Kornowski, Pharm.D.
CEO
Boston Pharmaceuticals
Olivier Leclerc
Senior Partner
McKinsey & Company
John Lepore, M.D.
CEO
ProFound Therapeutics
Mathai Mammen, M.D., Ph.D.
Chairman & CEO
FogPharma
Fiona Marshall, Ph.D.
President of Biomedical Research
Novartis
Antoine Papiernik
Chairman & Managing Partner
Sofinnova Partners
Kush Parmar, M.D., Ph.D.
Managing Partner
5AM Ventures
Cary Pfeffer, M.D.
Partner
Third Rock Ventures
Robert Plenge, M.D., Ph.D.
EVP, Chief Research Officer
Bristol Myers Squibb
Daniel Reich, M.D., Ph.D.
Chief, Translational Neuroradiology Section, NINDS, NIH Attending Neuroradiologist
NIH Clinical Center
Klaus Romero, M.D.
CEO
Critical Path Institute
Paul Peter Tak, M.D., Ph.D.
President & CEO
Candel Therapeutics
Nikhil Wagle, M.D.
VP & Global Head of Translational Medicine
Genentech
Douglas Williams, Ph.D.
CEO
TriArm Therapeutics